Drug or technology
6 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 8, 2026 · PHASE 1 TRIAL
ClinicalTrials.gov
Phase 1 trial registration with no posted results; study is actively recruiting and designed to establish safety and tolerability rather than efficacy.
SEP 8, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a Phase 3 RCT registration with no results posted; the study is actively recruiting and designed to test a novel PIK3CA inhibitor in advanced breast cancer, but outcome data are not yet available.
AUG 20, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
Phase 2 trial in a recruiting stage with no results reported; measures a surrogate endpoint (ctDNA clearance) in an adjuvant minimal residual disease setting.
AUG 19, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is an active Phase 3 trial registration with no results posted; the study is still recruiting and outcomes are not yet reported.
AUG 18, 2026 · PHASE 1 TRIAL
ClinicalTrials.gov
Phase 1 trial of a three-drug combination in metastatic breast cancer with dose-limiting toxicity as the primary endpoint; no results posted in this registry record.
AUG 10, 2026 · PHASE 1/2 TRIAL
ClinicalTrials.gov
This is a Phase 1b/2 trial registration with no results posted; the study is actively recruiting and designed to evaluate safety and efficacy of a novel agent in combination therapy for ER+/HER2− breast cancer.